CKD-379

CKD-379 is a pharmaceutical compound being developed by Chong Kun Dang Pharmaceutical Corporation. It is currently in early clinical development, with Phase I trials evaluating its pharmacokinetic characteristics and safety profile. The search results indicate that clinical trials have been conducted to assess the food effect on the drug's pharmacokinetics in healthy adult volunteers. It is being developed for Type 2 Diabetes. The drug appears to be in relatively early stages of development, with ongoing Phase I trials focused on establishing its basic pharmacokinetic profile and safety in healthy volunteers before proceeding to efficacy studies in diabetic patients. While the specific mechanism of action is not explicitly stated in the search results, it is positioned as a treatment for Type 2 Diabetes, which is a metabolic disorder characterized by high blood sugar levels due to insulin resistance or insufficient insulin production.